Fig. 1
Changes in bronchial RBM thickness in omalizumab responders (OR) and non-omalizumab responders (NOR) at baseline and after 12 and 36 months of anti-IgE treatment
Fig. 1 | Clinical and Translational Allergy
Changes in bronchial RBM thickness in omalizumab responders (OR) and non-omalizumab responders (NOR) at baseline and after 12 and 36 months of anti-IgE treatment